![]() |
|
---|---|
Systematic (IUPAC) name | |
ethyl 4-(butylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate | |
Clinical data | |
Pregnancy cat. | ? |
Legal status | Uncontrolled |
Routes | Oral |
Identifiers | |
CAS number | 34966-41-1 |
ATC code | None |
PubChem | CID 37015 |
ChemSpider | 33966 |
UNII | 8K93Z46WPY ![]() |
Chemical data | |
Formula | C15H22N4O2 |
Mol. mass | 290.36 g/mol |
SMILES | eMolecules & PubChem |
Cartazolate (SQ-65,396) is a drug of the pyrazolopyridine class. It acts as a GABAA receptor positive allosteric modulator at the barbiturate binding site of the complex and has anxiolytic effects in animals.[1][2][3][4] It is also known to act as an adenosine antagonist at the A1 and A2 subtypes and as a phosphodiesterase inhibitor.[5][6] Cartazolate was tested in human clinical trials and was found to be efficacious for anxiety but was never marketed.[7]
|
|
|